Abbott Introduces Next | 合法醫療器材資訊網

2020年2月18日—18,2020/PRNewswire/--Abbott(NYSE:ABT)todayannouncedithasreceivedCEMarkforthenewGallant™implantablecardioverter ...

Abbott Introduces Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity

- New Gallant™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patients unique clinical needs

- Gallant ICD and CRT-D devices feature a more comfortable design, preferred by patients without compromising on battery longevity or high-voltage output, which remain among the highest in the industry

ABBOTT PARK, Ill., Feb. 18, 2020 /PRNewswire[1]/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for the new Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, bringing the most advanced heart rhythm management capabilities along with a new set of benefits to people in Europe with abnormal hea...